山東新華製藥股份(00719.HK)年度純利升17.49%至3億元 末期息0.12元
格隆匯3月20日丨山東新華製藥股份(00719.HK)公佈年度業績,公司實現營業收入人民幣56.06億元(單位下同),同比增長6.89%;利潤總額3.81億元,同比增長14.76%;歸屬於上市公司股東的淨利潤3.00億元,同比增長17.49%;歸屬於上市公司股東的扣除非經常損益的淨利潤2.59億元,同比增長10.96%;基本每股收益0.48元,擬派末期息每股0.12元(含税)。
業績增長的主要原因是2019年公司狠抓市場開發,注重產品結構調整,生產經營繼續保持了良好發展態勢。
期內,公司發揮綜合優勢,狠抓市場營銷,原料藥主導品種繼續保持產銷兩旺態勢,格列美脲、卡巴匹林鈣等特色原料藥市場開發取得良好成效。紮實推進大製劑發展戰略,整合製劑營銷資源,製劑板塊營業收入實現快速增長,其中製劑戰略品種銷售保持高速增長。以新華醫藥電商創新園為依託,推進品牌聯盟戰略,啟動跨境電商業務,電子商務繼續保持快速增長。
此外,公司加大研發投入,2019年研發費用同比增長26%。格列美脲片、鹽酸西替利嗪片、頭孢拉定膠囊、卡託普利片4個產品5個規格於國內首家或前三通過一致性評價。取得鹽酸法舒地爾及其注射液1個仿製藥註冊批件,伏格列波糖片1個臨牀批件,獲得5個獸藥批准文號,完成了12個產品7個國家DMF申報。抗老年痴呆重大創新藥物OAB-14藥效學評價取得重要進展。
全年申請專利81件,獲得專利授權22件。"基於產業化關鍵技術的咖啡因綠色製備體系構建與規模開發"榮獲2018年度山東省科學技術進步二等獎,"原料藥生產過程中多元共沸物的連續化熱集成分離與精密控制技術"榮獲2019年度山東省技術發明二等獎。本公司被評為山東省技術創新示範企業,並順利通過國家企業技術中心評價。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.